Here are the latest G-BA decisions from the G-BA meeting held on 16 January 2025 on the early benefit assessments of Alecensa, Locametz, Fruzaqla, Eladynos, Soolantra, Zynlonta, Columvi, and Tepkinly. We are starting with very note-worthy decision on Alecensa and a decision on radiodiagnostic Locametz.
A complete database of all previous G-BA resolutions is in my membership.
- Alecensa (Alectinib); new indication: non-small cell lung cancer, ALK+, high risk of recurrence, adjuvant therapy – Hint of major additional benefit in one of two subgroups, none in the other – IQWiG gave a “No additional benefit recommendation for both subgroups”
- Locametz (Gozetotide); first-time dossier requirement: detection of PSMA-positive prostate cancer (mCRPC), PSMA-targeted therapy – Indication of considerable additional benefit in one of two subgroups, none in the other
- Fruzaqla (Fruquintinib); metastatic colorectal cancer, previously treated patients – Hint of minor additional benefit
- Eladynos (Abaloparatide); osteoporosis, postmenopausal women – removal of time restriction of previous decision
- Soolantra (Ivermectin); revoking decisions from 27 November 2015 and 21 January 2016, since the benefit assessment was ruled to be unlawful
- Zynlonta (Loncastuximab tesirin); relapsed or refractory diffuse large B-cell lymphoma – Request for RWE collection
- Columvi Glofitamab); relapsed or refractory diffuse large B-cell lymphoma – Request for RWE collection
- Tepkinly (Epcoritamab); relapsed or refractory diffuse large B-cell lymphoma – Request for RWE collection
Follow me on Instagram to never miss the latest G-BA decisions:
